Exabis Library
Welcome to the e-CCO Library!
P683: Patients with newly diagnosed fistulizing perianal Crohn's disease have a distinct microbial signature
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P683: Risk factors for fatigue in IBD patients.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P684: A first clinical trial of a novel narrow spectrum kinase inhibitor TOP1288 in patients with ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P684: Extra intravenous reinduction of ustekinumab on an already shortening interval is an effective optimisation strategy for patients with refractory Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P684: Increased risk of cardiovascular disease and high risk profiles compatible with metabolic syndrome in patients with Inflammatory Bowel Disease: a cross-sectional analysis of matched cohorts
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P684: Multiplex Gastrointestinal Pathogen Panel Testing is Associated with Higher Rates of Inflammatory Bowel Disease Therapy Escalation in Patients Hospitalised with Flare
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P684: Sleep disturbances in IBD patients without sedative therapy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P684: Vaccination strategies for IBD patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P685 Healthcare resource use associated with ferric maltol and IV iron treatment for iron deficiency anaemia in patients with inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
Wednesday, 3 March 2021, 4:11 PM by Dauren Ramankulov
P685: Early use of infliximab after seton technique for patients with Crohn's disease who initially presented with perianal fistulas
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P685: Gut microbiota in patients with Inflammatory Bowel Disease during remission
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P685: Improvement in patient-reported Inflammatory Bowel Disease Questionnaire outcomes, and relationship with disease activity, in tofacitinib-treated patients with ulcerative colitis: Data from the OCTAVE clinical trials
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P685: Patient’s performance and feedback by using home test faecal calprotectin as an objective reported outcome
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P685: Strong Response to SARS-CoV-2 Vaccine Additional Doses among Patients with Inflammatory Bowel Diseases
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P685: Switching from originator-infliximab to biosimilar-infliximab has no influence on health-related quality of life and clinical disease activity among patients with inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P686 Expression of CD39 ectonucleotidase on regulatory T cells and on T helper 17 cells in children with IBD receiving anti-TNF therapy
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P686: Application of dried blood spots for pharmacokinetic profiling of golimumab-treated patients with ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P686: Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn’s disease patients: PRACTICROHN study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P686: Neither high infliximab maintenance doses nor high trough levels trigger skin side effects of the drug: a prospective cross-sectional study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM